0RP logo

Tiziana Life Sciences DB:0RP Stock Report

Last Price

€1.16

Market Cap

€111.9m

7D

-17.1%

1Y

202.1%

Updated

24 Mar, 2025

Data

Company Financials

Tiziana Life Sciences Ltd

DB:0RP Stock Report

Market Cap: €111.9m

0RP Stock Overview

A biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. More details

0RP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Risk Analysis

Makes less than USD$1m in revenue ($0)

Earnings have declined by 4.3% per year over past 5 years

Highly volatile share price over the past 3 months compared to the German market


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Tiziana Life Sciences Ltd Competitors

Heidelberg Pharma

XTRA:HPHA

€123.0m

2invest

XTRA:2INV

€70.7m

4SC

DB:VSC

€28.5m

Formycon

XTRA:FYB

€470.6m

Price History & Performance

Summary of share price highs, lows and changes for Tiziana Life Sciences
Historical stock prices
Current Share PriceUS$1.16
52 Week HighUS$1.53
52 Week LowUS$0.34
Beta0.035
1 Month Change37.28%
3 Month Change58.90%
1 Year Change202.08%
3 Year Change14.85%
5 Year Changen/a
Change since IPO-10.77%

Recent News & Updates

Recent updates

Shareholder Returns

0RPDE BiotechsDE Market
7D-17.1%0.4%-1.3%
1Y202.1%-14.3%13.1%

Return vs Industry: 0RP exceeded the German Biotechs industry which returned -12.7% over the past year.

Return vs Market: 0RP exceeded the German Market which returned 13.3% over the past year.

Price Volatility

Is 0RP's price volatile compared to industry and market?
0RP volatility
0RP Average Weekly Movement17.5%
Biotechs Industry Average Movement9.1%
Market Average Movement5.4%
10% most volatile stocks in DE Market12.1%
10% least volatile stocks in DE Market2.8%

Stable Share Price: 0RP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 0RP's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
19989Ivor Elrifiwww.tizianalifesciences.com

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company’s lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn’s, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications.

Tiziana Life Sciences Ltd Fundamentals Summary

How do Tiziana Life Sciences's earnings and revenue compare to its market cap?
0RP fundamental statistics
Market cap€111.92m
Earnings (TTM)-€12.69m
Revenue (TTM)n/a

0.0x

P/S Ratio

-8.8x

P/E Ratio

Is 0RP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0RP income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$13.73m
Earnings-US$13.73m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.13
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 0RP perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/24 04:43
End of Day Share Price 2025/03/21 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Tiziana Life Sciences Ltd is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mayank MamtaniB. Riley Securities, Inc.
Robin CampbellEquity Development Limited
Raghuram SelvarajuH.C. Wainwright & Co.